alex rubinsteyn Profile picture
Machine learning, genomics, cancer immunotherapy, personalized vaccines. @CompMedUNC @UNC_Lineberger @OpenVax
Feb 25 19 tweets 6 min read
Preprint live: biorxiv.org/content/10.110…
tl;dr We did not disprove the role of T-cells in clearing SARS-CoV-2 (sorry to disappoint) but we did manage to make a vaccine which induces strong but useless T-cell responses against SARS-CoV-2. Details & guess at interpretation below
1/n Many SARS-CoV-2 vaccines present the immune system with the spike protein or the parts of the spike most vulnerable to neutralization (S1 portion or even just the RBD). This antigenic content can be made directly (protein subunit), encoded as mRNA, DNA, DNA in a virus, &c
2/n
Jun 15, 2021 26 tweets 12 min read
It's been a preprint for a while but a much improved version of our paper is out in @GenomeMedicine

"Landscape and selection of vaccine epitopes in SARS-CoV-2"

genomemedicine.biomedcentral.com/articles/10.11…

With @ChristofCSmith1 @KOimmuno @BenjaminGVincen + many others

Tweetorial:

1/ In Feb 2020 SARS-CoV-2 still felt far away, a twitter feed of China + isolated cases in other countries (remember #ncov2019?)

I was driving to NC to start my new job at @UNC_Lineberger and was thinking about making a peptide vaccine for SARS-CoV-2...

2/
Jun 5, 2020 26 tweets 12 min read
New paper on @biorxivpreprint:

"Landscape and Selection of Vaccine Epitopes in SARS-CoV-2"

(biorxiv.org/content/10.110…)

Collaboration with @ChristofCSmith1 @bgvincentlab @JuliaKodysh @timodonnell @glycam @Olivercgrant @PEPperCHIP @erikgarrison & others.

Thread:

(1/) There are a zoo of vaccine approaches to SARS-CoV-2:

Front-runners: inactivated virus (SinoVac), mRNA (BioNTech, Moderna), electroporated DNA (Inovio), adenovirus (CanSino, Oxford), rVSV (IAVI), rS (Novavax) &c

Missing from the list: peptides

2/